Heart Failure

The Practical Cardiology(TM) Heart Failure clinical resource center is an information hub for the latest in heart failure and heart failure management. With a focus on heart failure with reduced and preserved ejection fraction (HFrEF and HFpEF) this page features content including articles, videos, podcasts, and clinician-authored columns on FDA approvals, studies, guideline updates, and more.

Preterm Birth Associated with Increased Heart Failure Risk Throughout Adulthood

April 09, 2021

An analysis of nearly 4.2 million patients from a birth registry indicates being born preterm was linked to a significantly higher risk of developing heart failure during childhood and a 42% greater risk of heart failure in adulthood.

Implementation and Use of Patient-Reported Outcomes in Heart Failure with Stephen Greene, MD

April 07, 2021

Hear from Stephen Greene, MD, as he takes a deeper dive into a recent study he led comparing use of NYHA class vs. KCCQ-OS to capture changes in disease state among patients with heart failure with reduced ejection fraction.

Dapagliflozin Effective for Heart Failure, Irrespective of Patient Sex

March 31, 2021

An analysis of DAPA-HF indicates the efficacy and safety profile of dapagliflozin was consistent regardless of patient sex, highlighting the potential of the SGLT2 inhibitor for heart failure patients.

Patient-Reported Outcomes Best NYHA Class for Capturing Progression of Heart Failure

March 25, 2021

An analysis of more than 2k HFrEF patients from the CHAMP-HF registry indicates changes in KCCQ-OS may be a more accurate way of capturing changes in disease state than New York Heart Association class.

AHA Study Links 4 Major Conditions to More than 60% of COVID-19 Hospitalizations

February 25, 2021

An analysis using data from the CDC, COVID-NET, and the COVID Tracking Project suggests nearly 2 out of 3 COVID-19 hospitalizations in the US were attributable to obesity, hypertension, diabetes, and heart failure.

FDA Expands Label for Sacubitril/Valsartan (Entresto) to Include Some HFpEF Patients

February 16, 2021

Novartis announced the US FDA has expanded the label for sacubitril/valsartan (Entresto) to include reducing the risk of CV death and hospitalizations for heart failure among patients with chronic heart failure.

Heart Failure Cases on the Rise Across the Globe

February 12, 2021

An analysis of data from 195 countries over a nearly 3 decade period indicates prevalence and burden of heart failure have continued to grow since 1990.

Study Suggests Coffee Consumption Decreases Heart Failure Risk

February 09, 2021

An analysis of data from a trio of major cardiovascular studies details the apparent decrease in risk of incident heart failure associated with increased intake of coffee.

GLS-Guided Therapy Could Reduce Impact of Cardiotoxicity from Chemotherapy

February 02, 2021

The SUCCOUR trial indicates GLS-guided cardioprotective therapy could be more effective at reducing the impact of cancer therapy-related cardiac dysfunction and incidence of cardiotoxicity than LVEF-guided therapy in patients exposed to anthracyclines.

FDA Approves Vericiguat (Verquvo) for Treatment of Heart Failure

January 20, 2021

The US FDA has approved vericiguat (Verquvo) for reducing the risk of cardiovascular death and heart failure hospitalization following a hospitalization for heart failure or need for outpatient intravenous diuretics in patients with HFrEF.